Engineering better solutions for people with heart failure

HemoCath

About HemoCath

HemoCath pioneers advancements at the crossroads of Medtech and Digital Health, aiming to enhance care for individuals with heart failure (HF).

​The versatile and scalable HemoCath™ AI Platform enables proactive AI-data-driven management of patients with acute HF from diagnosis to treatment and monitoring for all hospital heart procedures.

​The user-friendly integrated Platform includes the HemoCath™ PA catheter securely connected to the Luc™ AI Cloud to continuously measure and monitor PAP & CVP, the leading indicators of heart congestion, allowing early targeted therapy.

The vital health information remains easily available to the managing clinician, supporting optimal dosing of guideline-directed medical therapy (GDMT) across the entire spectrum of HF.

​Several clinical trials provide clinical evidence of a significant improvement in cardiac care and reduction in hospital stay ​with PAP-guided HF management.

Management Team 

​Eric Caron
Chief Executive Officer, Co-Founder, Board Member
Entrepreneur, CEO and founder with extensive experience in the medical devices, digital health, and high-tech industries. Proven track record in guiding ventures from initial concept through product commercialization and successful exit. With over 25 years of industry and leadership experience, Eric has held diverse roles across engineering R&D, product development, manufacturing, commercialization, operations, finance, and sales & marketing. He holds a BS in electrical/software Engineering and an MBA. 

​Christopher Glover, MD, FRCPC
Chief Medical Officer
Dr. Christopher Glover is Interventional Cardiologist and Director of Cardiac Catheterization at the University of Ottawa Heart Institute. Dr. Glover is also Associate Professor and Director of Education and Clinical Services in the division of cardiology at the University of Ottawa. His expertise in valve diseases and transcatheter valve replacements was achieved overtime through 20+ years as an interventional cardiologist. ​​

​Des Regan
Chief Technology Officer
Des is an expert in engineering development of novel medical devices, with an impressive track record over the past 30 years. He founded and lead a number of startup companies developing medical devices in Ireland.  Des has been Director of Product Development since 2003 with established companies such as Nordson Medical, Phillips Medisize and Medtronic. Inventor on 23 patents in the medical field. He holds a BS and MS in mechanical engineering.

​Michael Nagy
Chief Regulatory Officer
Michael Nagy, MSEE Case Western Reserve, has led advanced engineering teams for 33 years at a series of successful start-ups. He has transformed breakthrough microsensor, microelectronics, and micro-optics technologies into products for a variety of industries. In 2008, he co-founded Endotronix and led development of its wireless implantable sensor system from inception through current PMA trials. Inventor on 27 US patents.

​Robert Orr
Chief Financial Officer, Board Member
Seasoned corporate development strategist with 30+ years of executive and public practice experience. Chartered Professional Accountant, Chartered Business Valuators and senior member of American Society of Appraiser with a speciality in business valuation. Currently, co-founder & CEO of Life360 Innovations, commercializing a medical device for men with urinary incontinence. In addition, a board member and advisor for a number of companies.

Memorial tribute to Dr. Luc Bilodeau

MEMORIAL tribute

Contact Us

Locations:

USA   
​Austin, Texas, USA

IRELAND   
​​102 ATU iHubs, Dublin Road, Galway, H91 DCH9, Ireland